About this trial
This study looks at how well different types of phytocannabinoids, like cannabidiol (CBD) and a mix of THC and CBD, can help reduce pain and other symptoms caused by chemotherapy in breast and colon cancer survivors. Chemotherapy can lead to a condition called peripheral neuropathy, which causes pain, tingling, and numbness. This trial hopes to see if phytocannabinoids can improve these symptoms and quality of life for patients.
The trial's ID is NCT06731894. It is a Phase 2 trial, which means it is looking at how well the treatments work and how safe they are. This study is regulated by the FDA and aims to include about 120 participants.
Who can join
Anyone 18 years or older can join, including men and women. Participants need to have symptoms from chemotherapy that include neuropathy. They must also be able to read and understand English. Some health conditions may prevent joining, like recent chemotherapy or certain mental health issues. The trial team will check to see if you meet these criteria.
Conditions
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of three groups. One group will take CBD, another will take a mix of THC and CBD, and the last group will take a placebo, which looks like the real medicine but has no active ingredients. Each group will follow a specific schedule for taking their treatment over two cycles, each lasting 28 days. All groups will also provide urine samples during the study.
Where
This trial is running at 2 locations in the United States. All of them are currently recruiting.
City of Hope at Irvine Lennar
Irvine, California
City of Hope Medical Center
Duarte, California